ID

44393

Description

c-Met Second-Line Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02115373

Link

https://clinicaltrials.gov/show/NCT02115373

Keywords

Versions (2)
  1. 10/28/19 10/28/19 -
  2. 9/20/21 9/20/21 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

September 20, 2021

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Carcinoma, Hepatocellular NCT02115373

English

Eligibility Carcinoma, Hepatocellular NCT02115373

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically or cytologically confirmed hcc
Description

Liver carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C2239176
child pugh class a liver function score
Description

Liver function Child-Pugh Classification

Data type

boolean

Alias
UMLS CUI [1,1]
C0232741
UMLS CUI [1,2]
C4050412
for phase 2 only: met+ status
Description

MET Positive

Data type

boolean

Alias
UMLS CUI [1]
C4330600
male or female, 18 years of age or older
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
measurable disease in accordance with response evaluation criteria in solid tumors (recist) version 1.1
Description

Measurable Disease

Data type

boolean

Alias
UMLS CUI [1]
C1513041
eastern cooperative oncology group (ecog) performance status (ps) 0-1 (inclusive)
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
availability of a pretreatment tumor biopsy (excluding fine needle aspiration and cytology samples) taken after the subject has discontinued sorafenib and within 28 days before the day of first dosing with msc2156119j. from the pretreatment biopsy either a formalin-fixed (formalin fixation is mandatory) paraffin-embedded block with tumor tissue (preferred) or at least 15 unstained slides must be sent to the central laboratory prior to enrollment. an associated pathology report must also be sent with the sample
Description

Tumor Biopsy Pretreatment | Exception Fine needle aspiration biopsy | Exception Cytologic material | Sorafenib Discontinued | Tepotinib | Tumor tissue Formalin-fixed paraffin-embedded tissue specimen Block | Unstained Specimen Quantity | Pathology report

Data type

boolean

Alias
UMLS CUI [1,1]
C0027651
UMLS CUI [1,2]
C0005558
UMLS CUI [1,3]
C3539076
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C1510483
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0225355
UMLS CUI [4,1]
C1516119
UMLS CUI [4,2]
C1444662
UMLS CUI [5]
C4287799
UMLS CUI [6,1]
C0475358
UMLS CUI [6,2]
C2711483
UMLS CUI [6,3]
C1533157
UMLS CUI [7,1]
C1883469
UMLS CUI [7,2]
C1265611
UMLS CUI [8]
C0807321
previously treated with sorafenib for greater than or equal to 4 weeks and discontinued sorafenib treatment at least 14 days prior to day 1 due to either intolerance or radiographic progression
Description

Sorafenib | Sorafenib Discontinued | Intolerance to Sorafenib | Disease Progression Radiography

Data type

boolean

Alias
UMLS CUI [1]
C1516119
UMLS CUI [2,1]
C1516119
UMLS CUI [2,2]
C1444662
UMLS CUI [3,1]
C1744706
UMLS CUI [3,2]
C1516119
UMLS CUI [4,1]
C0242656
UMLS CUI [4,2]
C0034571
signed and dated informed consent indicating that the subject (or legally acceptable representative if applicable by local laws) has been informed of all the pertinent aspects of the trial prior to enrollment
Description

Informed Consent | Informed Consent Patient Representative

Data type

boolean

Alias
UMLS CUI [1]
C0021430
UMLS CUI [2,1]
C0021430
UMLS CUI [2,2]
C0030701
willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other trial procedures
Description

Protocol Compliance

Data type

boolean

Alias
UMLS CUI [1]
C0525058
life expectancy of at least 3 months as judged by the investigator
Description

Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior systemic anticancer treatment for advanced hcc (except for sorafenib as described in the inclusion criteria)
Description

Cancer treatment Systemic Advanced Adult Hepatocellular Carcinoma | Exception Sorafenib

Data type

boolean

Alias
UMLS CUI [1,1]
C0920425
UMLS CUI [1,2]
C0205373
UMLS CUI [1,3]
C1706732
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C1516119
prior treatment with any agent targeting the hepatocyte growth factor (hgf)/c-met pathway
Description

Targeted Therapy Hepatocyte Growth Factor | Targeted Therapy C-MET

Data type

boolean

Alias
UMLS CUI [1,1]
C2985566
UMLS CUI [1,2]
C0062534
UMLS CUI [2,1]
C2985566
UMLS CUI [2,2]
C1456828
local-regional therapy within 4 weeks before day 1
Description

Therapy Local-Regional

Data type

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1947913
impaired cardiac function
Description

Decreased cardiac function

Data type

boolean

Alias
UMLS CUI [1]
C0232166
other protocol defined exclusion criteria could apply
Description

Exclusion Criteria Study Protocol

Data type

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C2348563
Back to the top of the page

Similar models

Eligibility Carcinoma, Hepatocellular NCT02115373

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Liver carcinoma
Item
histologically or cytologically confirmed hcc
boolean
C2239176 (UMLS CUI [1])
Liver function Child-Pugh Classification
Item
child pugh class a liver function score
boolean
C0232741 (UMLS CUI [1,1])
C4050412 (UMLS CUI [1,2])
MET Positive
Item
for phase 2 only: met+ status
boolean
C4330600 (UMLS CUI [1])
Age
Item
male or female, 18 years of age or older
boolean
C0001779 (UMLS CUI [1])
Measurable Disease
Item
measurable disease in accordance with response evaluation criteria in solid tumors (recist) version 1.1
boolean
C1513041 (UMLS CUI [1])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status (ps) 0-1 (inclusive)
boolean
C1520224 (UMLS CUI [1])
Tumor Biopsy Pretreatment | Exception Fine needle aspiration biopsy | Exception Cytologic material | Sorafenib Discontinued | Tepotinib | Tumor tissue Formalin-fixed paraffin-embedded tissue specimen Block | Unstained Specimen Quantity | Pathology report
Item
availability of a pretreatment tumor biopsy (excluding fine needle aspiration and cytology samples) taken after the subject has discontinued sorafenib and within 28 days before the day of first dosing with msc2156119j. from the pretreatment biopsy either a formalin-fixed (formalin fixation is mandatory) paraffin-embedded block with tumor tissue (preferred) or at least 15 unstained slides must be sent to the central laboratory prior to enrollment. an associated pathology report must also be sent with the sample
boolean
C0027651 (UMLS CUI [1,1])
C0005558 (UMLS CUI [1,2])
C3539076 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C1510483 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0225355 (UMLS CUI [3,2])
C1516119 (UMLS CUI [4,1])
C1444662 (UMLS CUI [4,2])
C4287799 (UMLS CUI [5])
C0475358 (UMLS CUI [6,1])
C2711483 (UMLS CUI [6,2])
C1533157 (UMLS CUI [6,3])
C1883469 (UMLS CUI [7,1])
C1265611 (UMLS CUI [7,2])
C0807321 (UMLS CUI [8])
Sorafenib | Sorafenib Discontinued | Intolerance to Sorafenib | Disease Progression Radiography
Item
previously treated with sorafenib for greater than or equal to 4 weeks and discontinued sorafenib treatment at least 14 days prior to day 1 due to either intolerance or radiographic progression
boolean
C1516119 (UMLS CUI [1])
C1516119 (UMLS CUI [2,1])
C1444662 (UMLS CUI [2,2])
C1744706 (UMLS CUI [3,1])
C1516119 (UMLS CUI [3,2])
C0242656 (UMLS CUI [4,1])
C0034571 (UMLS CUI [4,2])
Informed Consent | Informed Consent Patient Representative
Item
signed and dated informed consent indicating that the subject (or legally acceptable representative if applicable by local laws) has been informed of all the pertinent aspects of the trial prior to enrollment
boolean
C0021430 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C0030701 (UMLS CUI [2,2])
Protocol Compliance
Item
willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other trial procedures
boolean
C0525058 (UMLS CUI [1])
Life Expectancy
Item
life expectancy of at least 3 months as judged by the investigator
boolean
C0023671 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Cancer treatment Systemic Advanced Adult Hepatocellular Carcinoma | Exception Sorafenib
Item
prior systemic anticancer treatment for advanced hcc (except for sorafenib as described in the inclusion criteria)
boolean
C0920425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C1706732 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C1516119 (UMLS CUI [2,2])
Targeted Therapy Hepatocyte Growth Factor | Targeted Therapy C-MET
Item
prior treatment with any agent targeting the hepatocyte growth factor (hgf)/c-met pathway
boolean
C2985566 (UMLS CUI [1,1])
C0062534 (UMLS CUI [1,2])
C2985566 (UMLS CUI [2,1])
C1456828 (UMLS CUI [2,2])
Therapy Local-Regional
Item
local-regional therapy within 4 weeks before day 1
boolean
C0087111 (UMLS CUI [1,1])
C1947913 (UMLS CUI [1,2])
Decreased cardiac function
Item
impaired cardiac function
boolean
C0232166 (UMLS CUI [1])
Exclusion Criteria Study Protocol
Item
other protocol defined exclusion criteria could apply
boolean
C0680251 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial